Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH-UP: Upadacitinib vs Dupilumab in Moderate to Severe Atopic Dermatitis with Inadequate Response to Dupilumab
jRCT2061240026Phase 4Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in atopic dermatitis (AD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Simultaneous EASI 90 and WP-NRS 0/1 at Week 8. Started Jul 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061240026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240026.